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Abstract
Tannerella forsythia is a gram-negative bacteria, which is strongly associated with the development of periodontal disease.
Karilysin is a newly identified metalloprotease-like enzyme, that is secreted from T. forsythia. Karilysin modulates the host
immune response and is therefore considered a likely drug target. In this study peptides were selected towards the catalytic
domain from Karilysin (Kly18) by phage display. The peptides were linear with low micromolar binding affinities. The two
best binders (peptide14 and peptide15), shared the consensus sequence XWFPXXXGGG. A peptide15 fusion with Maltose
Binding protein (MBP) was produced with peptide15 fused to the N-terminus of MBP. The peptide15-MBP was expressed in
E. coli and the purified fusion-protein was used to verify Kly18 specific binding. Chemically synthesised peptide15
(SWFPLRSGGG) could inhibit the enzymatic activity of both Kly18 and intact Karilysin (Kly48). Furthermore, peptide15 could
slow down the autoprocessing of intact Kly48 to Kly18. The WFP motif was important for inhibition and a truncation study
further demonstrated that the N-terminal serine was also essential for Kly18 inhibition. The SWFP peptide had a Ki value in
the low micromolar range, which was similar to the intact peptide15. In conclusion SWFP is the first reported inhibitor of
Karilysin and can be used as a valuable tool in structure-function studies of Karilysin.
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Introduction
Periodontitis is a serious bacterial infection-driven inflammatory
disease affecting the periodontium, i.e., the tissues that surround
and support the teeth. The ‘red complex’ is a term used for the
three bacterial taxa that are considered the major period-
ontopathogens (Treponema denticola, Porphyromonas gingivalis and
Tannerella forsythia) that lead to disease development [1]. These
pathogens all produce high levels of extracellular proteolytic
activity [2–8], which contributes to the periodontitis symptoms;
loss of attachment between the tooth and the gingiva, which is due
to bone degradation and weakening of the soft tissues surrounding
the root of a tooth. This ultimately leads to formation of deep
periodontal pockets and teeth loss [9]. Furthermore, accumulating
evidence suggests that severe forms of periodontitis contribute to
development of the systemic diseases, stroke, diabetes and
rheumatoid arthritis [10–14]. Current periodontitis therapies are
based upon mechanical removal of supra- and subgingival
bacterial plaque from the tooth surface in conjunction with the
use of antibiotics. Unfortunately, this treatment is not always fully
effective, and focus was therefore directed towards development of
protease inhibitors as an alternative weapon towards the period-
ontopathogen effects. In fact, a factor Xa inhibitor could inhibit
the P. gingivalis gingipain proteases RgpA and RgpB and was
bactericidal towards P. gingivalis [15]. Furthermore, chlorhexidine
and benzamidine were used successfully to inhibit P. gingivalis
gingipains [16,17]. Furthermore, doxycycline could inhibit prote-
ase activity from P. gingivalis and T. denticola [18].
T. forsythia is a gram-negative bacteria, which secrete proteases
that act as virulence factors (PrtH, a cysteine protease and BspA, a
trypsin-like protease). PrtH displays hemolysin activity and one
study suggested that BspA mediates T. forsythia attachment to
fibronectin and fibrinogen [19–21]. Karilysin, a newly identified
metalloprotease isolated from T. forsythia [6] is secreted as a 472-
residue protein and has the following composition; a 20-residue
signal sequence, a 14-residue pro-peptide, an 18 kDa catalytic
peptidase domain and a 30 kDa C-terminal domain of unknown
function. The full length enzyme could be recombinantly
expressed but the enzyme matured through sequential autolysis,
by first generating a fully active 48 kDa variant, followed by
formation of the catalytic domain (named Kly18) [6,22]. Kly18
structural analysis demonstrated a similarity to mammalian matrix
metalloproteinases (MMPs) [22]. MMPs are a separate family
within the ‘metzincin’ clan of MPs and participate in turnover of
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extracellular-matrix components and selective activation/inacti-
vation of other proteins and enzymes. The MMP activity is tightly
regulated, however uncontrolled MMP-proteolysis can occur,
leading to tissue destruction, apoptosis and inflammation [23].
Metalloproteases derived from microbial pathogens were docu-
mented as important virulence factors contributing to evasion of
antimicrobial mechanisms of the innate immune system [24].
Only limited information is available on the biology of
Karilysin. Recent data demonstrated that Karilysin can inactivate
the antimicrobial peptide LL-37 by proteolytic cleavage [7]. This
suggests that Karilysin can contribute to evasion of the human
immune response. This hypothesis has been further substantiated
by recent findings that Karilysin-expressing T. forsythia isolates
inhibits all pathways of the complement system by Karilysin-
mediated degradation of complement system proteins (mannose-
binding lectin, ficolin-2, ficolin-3, C4 and C5) [25]. For these
reasons Karilysin is considered a potential target for therapeutic
intervention but no Karilysin inhibitors currently exist.
In this study phage display was used to identify a peptide that
specifically bound Karilysin and efficiently inhibited the proteo-
lytic activity of Karilysin.
Materials and Methods
Miscellaneous Reagents
Karilysin catalytic domain (Kly18) and intact Kly48 were
produced as previously described [6]. Active human MMP-3
catalytic domain, Bovine Serum Albumine (BSA), LB-medium and
FITC-Casein were from Sigma-Aldrich. Maltose-binding protein
(MBP) was from ProSpec-Tany TechnoGene Ltd. Peroxidase
conjugated mouse anti-M13 phage monoclonal antibody, LMW
(Low Molecular Weight)-SDS Marker and 1 ml MBPTrap HP
columns were from GE-Healthcare. Peptide phage libraries (7-mer
and 7-mer cysteine-constrained), pMAL-pIII vector, M13KE
insert extension primer (NEB #E8101), 296 gIII sequencing
primer (NEB #S1259), monoclonal anti-MBP HRP-conjugate,
EagI and Acc65I were from New England Biolabs. Maxisorp
microtiter plates and black fluorescence non-surface treated plates
were both from NUNC. OPD-tablets (o-Phenylenediamine dihy-
drochloride) were from DAKO. All peptides were synthesised by
Genscript. T4-DNA ligase was from Invitrogen. QIAquick gel
extraction kit was from QIAgen. Ampicillin was from Calbiochem.
Isopropyl b-D-thiogalactoside (IPTG) was from VWR.
Biopanning
Phage libraries displaying seven amino acids in random
sequence order at the N-terminal end of protein III were used
for affinity selection of peptide binders towards Kly18. Both a
linear and a constrained version of the peptide library were used
for the selection. Microtiter plates were coated at 4uC for 16 hours
with purified Kly18 at 0.66 mM using 100 ml per well. These plates
were subsequently washed in PBS (20 mM sodium phosphate,
150 mM NaCl, pH 7.4) supplemented with 0.05% Tween-20
(PBS-T) and then blocked with 4% BSA in PBS for 2 h at room
temperature. Bacteriophage at 1011 pfu/100 ml were used for each
panning round. The constrained and linear libraries were mixed
and panned together as a mixture in PBS supplemented with 0.1%
Tween20, pH = 7.4. After incubation for one hour at room
temperature plates were washed ten times with PBS-T (0.1%
Tween20) and bound peptide-phage were eluted with glycine/
HCl, pH = 2.2 for 10 min. followed by neutralisation with Tris–
base, pH = 9.0. Eluted phage were used to infect exponentially
growing TG1 cells overnight at 37uC. The following day peptide-
phage were precipitated from the cell supernatant with phage
precipitation buffer (20% (w/v) PEG6000), 2.5 M NaCl) and re-
dissolved in PBS as described [26]. After four rounds of panning,
single clones were isolated and tested for Kly18 binding in phage
ELISA (see below). Single stranded DNA was extracted from
positive clones according to [27] and the DNA was sequenced in
the region corresponding to the random peptide region.
Phage ELISA
Kly18 wells were coated and blocked as above. The following
washes and incubations were performed at room temperature.
After blocking, the plates were washed three times in PBS-T and
one hundred ml solutions of the individual phage clones diluted 1:1
in 4% BSA/PBS were added in a concentration of 161010 pfu/ml
and further incubated for one hour. Wells were washed ten times
with PBS-T and next 100 ml of peroxidase conjugated mouse anti-
M13 monoclonal antibody diluted 1/1000 in 2% BSA/PBS,
pH = 7.4 was added and incubated for one hour. The plates were
washed ten times and detection was carried out by adding 100 ml
of an OPD solution (1 OPD-tablet dissolved in 3 ml H2O and 5 ml
30% H2O2). The reaction was stopped by adding 100 ml of 1 M
H2SO4 and absorbance values (A) were measured at 490 nm using
an immunoreader (Emax).
Estimation of Peptide-phage Binding Affinity by the Use
of Inhibition ELISA
Nunc Maxisorp plates were coated with Kly18 and blocked as
described earlier. Titration curves of each clone revealed the
phage concentration that gave half-maximum response, and this
concentration was used for the individual inhibition assays. The
inhibition assay was performed essentially as described previously
[28]. Briefly, the individual phage clones were incubated with
decreasing concentrations of Kly18 in 4% skimmed milk/PBS for
1 hour with extensive mixing. The mix was added to Kly18 coated
and blocked wells and the unbound free phage were allowed to
bind for 1 hour. Wells were washed with PBS-T five times and
developed as above. The absorbance values were measured at
490 nm after 30 min of incubation at 22uC. Absorbance values
determined at each Kly18 concentration (A) were divided by the
absorbance measured in the presence of zero Kly18 (A0), thereby
yielding normalized values (A/A0). These values were plotted
against the Kly18 concentration to construct the inhibition curve.
Curve fitting revealed the Kly18 concentration required for 50%
inhibition (I50) as described previously [28]. The assay was
performed in triplicate.
Subcloning, Expression and Purification of the Maltose
Binding Protein-peptide15 Fusion Protein
Peptide15 phage single stranded DNA was isolated as above
and 25 ng of DNA was used as template for amplification of the
peptide15 DNA by PCR using the M13KE insert extension
primer and the 296 gIII sequencing primer. The programme used
was 25 cycles of 95uC for 30 sec., 55uC for 30 sec. and 72uC for
30 sec. The PCR product was isolated as a single DNA band after
agarose gel electrophoresis and digested with Acc65I and EagI1.
The peptide15 DNA with flanking sequences was again purified
after agarose gel electrophoresis. The peptide15 DNA was
subcloned into Acc65I/EagI digested pMAL-pIII vector by T4-
DNA ligase and transformed into chemocompetent TG1 cells.
Clones were amplified, sequenced and preserved as glycerol stocks.
A MBP-peptide15 clone was used for fusion-protein production by
expansion in LB-medium (supplemented with 10 mM MgCl2,
0.2% glucose and 1 mM ampicillin) and when OD600 = 0.6 was
reached the culture was induced with 1 mM IPTG for 3 hours at
Tetrapeptide Inhibitor of Karilysin
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30uC. The periplasmic fraction was isolated according to [29] and
extensively dialysed into buffer A (20 mM Tris-HCl, 200 mM
NaCl, 1 mM EDTA, pH 7.4). The dialysed fraction was applied
to a 1 ml MBPTrap HP column at a flow rate of 1 ml/min and
following extensive column wash with buffer A, MBP-peptide15
was eluted with 100% buffer B (20 mM Tris-HCl, 200 mM NaCl,
1 mM EDTA, 10 mM Maltose, pH 7.4). After dialysis into PBS,
MBP-peptide15 purity was confirmed by SDS-PAGE.
Kly18 Detection by MBP-peptide15 ELISA
Kly18 and human MMP-3 catalytic domains were coated at the
concentration of 0.66 mM. Blank wells were included for
background determination. All wells were blocked in 4% BSA/
PBS for 1 hour. After wash with PBS-T (5 times), MBP-peptide15
in 2% BSA/PBS diluted to 25 mg/ml was incubated for one hour
with shaking. After wash with PBS-T (5 times), a monoclonal anti-
MBP HRP-conjugate was added diluted 1:5000 in 2% BSA/PBS.
Wells were washed ten times in PBS-T and developed with OPD
substrate as above. To demonstrate that binding to Kly18 was
mediated by peptide15 and not by MBP itself, control ELISA
experiments were performed using MBP instead of MBP-
peptide15.
Figure 1. Phage ELISA test of nineteen selected clones after four panning rounds, peptide sequences and estimated apparent
afffinity. A) Optical density responses detected after the binding of peptide-phage to immobilized Kly18 are shown. Background binding to BSA has
been subtracted for each clone. Clones with signals above 0.5 were deemed positive and further sequenced. B) Peptide-phage clones were tested in
inhibition ELISA for estimation of affinity. All clones (except clone 13) shared the WXP motif.
doi:10.1371/journal.pone.0048537.g001
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Assay for Monitoring Peptide15 Inhibitory Activity
towards Kly18
Kly18 and Kly48 protease activities were monitored essentially
as described [6]. One hundred ml working volumes were used in
black untreated polypropylene microtitre plates and FITC-casein
was used as the substrate. Assays were performed at 37uC using
500 nM of Kly18 (or Kly48) in assay buffer (100 mM Tris-HCl,
5mM CaCl2, pH 8.0), at a FITC-casein concentration of 25 mg/
ml. Released fluorescence was measured using a micro-titer plate
reader at excitation/emission wavelengths of 485/538 nm. Pep-
tides were dissolved in Milli Q water and added in varying
molarities. The assay setup was as follows; Kly18 (or Kly48) was
diluted in assay buffer together with peptide, followed by 30
minutes incubation on a vertical shaker at 22uC. Then FITC-
casein was added and fluorescence formation was monitored at
37uC for 90 minutes with measurements every ten minutes. For
estimation of inhibition constants (Ki) for peptide inhibition of
Kly18, a fixed amount of Kly18 (500 nM as above) was incubated
with varying concentrations of FITC-casein (5–25 mg/ml) in the
presence of varying amounts of Kly18 peptide inhibitor (0–
10 mM). Enzyme velocities were plotted, curves fitted and
determination of Ki was performed using GraphPad Prism 5.04
using the macro for competitive inhibitor.
Assay for Monitoring the Effect of Peptide15 on the
Auto-processing of Kly48
Karilysin (Kly48) at 13 mM was incubated at 37uC in 50 mM
Tris-HCl, 2.5 mM CaCl2, 0.02% NaN3 pH 8.0 alone or in the
presence of the peptide SWFPL at 455 mM. At different time
points samples were withdrawn and the Kly48 autocatalytic
processing was monitored by SDS-PAGE using 10% gels and the
Tris-HCl/Tricine buffer system [30]. Gels were stained with 0.1%
Coomassie Brilliant Blue R-250 in 10% acetic acid followed by
destaining. Samples were run alongside a Low Molecular Weight
SDS-PAGE Marker.
Results and Discussion
Isolation of Kly18 Binding Peptide-phage
Peptide phage display is an excellent tool for fast identification
of lead structures that can be further modified as protease
inhibitors [31]. In the present study 7-mer peptide libraries were
Figure 2. Peptide15 inhibits the proteolytic activity of Kly18. Peptide15 was pre-incubated with Kly18 in varying concentrations followed by
addition of the substrate FITC-casein. The peptide15 inhibitory effect was seen as a decrease in Relative Fluorescence Units (RFU) in a dose-response
manner. Error bars represent standard deviations between three experiments.
doi:10.1371/journal.pone.0048537.g002
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used for bio-panning against the catalytic domain from Karilysin
(Kly18). A cyclic 7-mer disulfide-constrained library
(ACX7CGGGS) and a linear 7-mer library (X7GGGS) were
mixed and used for selection on Kly18. Both libraries were fused
to the N-terminal of protein III and displayed on phage. After four
bio-panning rounds against surface-immobilized Kly18 a large
enrichment in Kly18 binding phage was observed (.500
compared to the BSA control, data not shown). Nineteen clones
were amplified and phage ELISA revealed seven Kly18-binders,
peptide-phage 9,11,13,14,15,16,19 (Figure 1A). All seven peptide-
phage displayed apparent affinities in the low micromolar range
(Figure 1B). Only linear binders were isolated suggesting that the
linear binders were of higher affinity than any potential cyclic
peptides present in the library. In bio-panning experiments against
other protein targets, we have used the same approach of mixing
linear and cyclic libraries, but in these cases we isolated
constrained peptides as well as linear peptides (unpublished). This
suggested that we could exclude the possibility of a higher growth
rate of the linear peptide library as the reason why we only isolated
linear binders. All identified Kly18-binding peptide-phage (except
peptide13) had the WXP motif, clearly demonstrating that these
amino acids are important for Kly18 binding (Figure 1B).
Interestingly, no peptides were found with the WXP motif in
position 1–3 and all the peptides had the WXP peptide motif
placed in position 2–4, thereby suggesting that an amino acid is
essential in position one prior to the WXP motif for structural
stability. Furthermore, it was evident that the X-position in the
Kly18-binding motif was dependent upon basic amino acids
(arginine/lysine) or bulky hydrophobic residues (leucine/phenyl-
alanine) (Figure 1B). A decision was made to further focus on
peptide15 (SWFPLRSGGGS).
Figure 3. Peptide15 displays the characteristics of a competitive inhibitor. Shown are 1/V-1/S plot of peptide15 inhibition of Kly18. Kly18
was pre-incubated with fixed concentrations of peptide15 (10 mM and 30 mM) for 30 minutes, followed by incubation with varying concentrations of
FITC-casein (5–50 mg/ml). As seen from the Lineweaver-Burke plot the Y-intercept is approximately the same for un-inhibited Kly18 as Kly18 inhibited
with 10 mM and 30 mM, respectively. This suggested that peptide15 was a competitive inhibitor of Kly18. Linear regression lines were made using
SigmaPlot 11.0. Data represent mean values from three experiments per substrate concentration.
doi:10.1371/journal.pone.0048537.g003
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Free Soluble Peptide15 Inhibits Kly18 Proteolytic Activity
Peptide15 was chemically synthesised for activity testing.
Initially, the peptide was synthesised in its entirety, mimicking all
of the sequence displayed on phage. The peptide15 N-terminal
was free during panning, however the C-terminal was fused to the
phage. Consequently, peptide15 did not have a free negatively
charged carboxylate at its C-terminal during panning. Therefore,
in order to limit an effect of a C-terminal carboxylate, peptide15
was synthesised with a C-terminal amidation to block any
unwanted C-terminal effects. The peptide15 synthesised was
therefore (NH2)-SWFPLRSGGGS-(CONH2). The Kly18 proteo-
lytic activity was monitored with FITC-casein as the substrate and
peptide15 inhibited Kly18-mediated FITC-casein cleavage in a
dose-response manner (Figure 2). Furthermore, peptide15 dis-
played the characteristics of a competitive inhibitor as shown from
a 1/V-1/S plot of peptide15 inhibition of Kly18. As seen from the
Lineweaver-Burke plot the Y-intercept is approximately the same
for un-inhibited Kly18 as Kly18 inhibited with 10 mM peptide15
and 30 mM peptide15, respectively (Figure 3). This suggested that
peptide15 was a competitive inhibitor of Kly18.
To investigate the importance of the peptide15 WFP motif for
Kly18 inhibition a control peptide was chemically synthesised with
the WFP motif replaced by a triple alanine, (NH2)-
SAAALRSGGGS-(CONH2). Even in a very high dose (174 mM)
the control peptide had a curve similar to that of Kly18 with no
peptide present, thereby demonstrating that the WFP motif was
crucial for inhibition of Kly18 (Figure 4).
Peptide15 Truncation Study and Comparative Kinetic
Analysis
Peptide15 was synthesised in its entirety, including the linker
sequence attached to the phage (GGGS) and the question arose if
the amino acids flanking the WFP motif were necessary for Kly18
inhibition. To answer this, fifteen truncation variants of peptide15
were designed, termed 15-1 to 15–16 and the peptide15 lead
structure was named 15-0 (Table 1). Peptide version 15-9
(WFPLRSGGGS) was too hydrophobic for synthesis but all others
could be produced. Initially all peptide versions were screened in a
relatively high single concentration (87 mM) to reveal if omission of
single amino acid residues displayed dramatic effects on Kly18
inhibition. The peptide15 truncated version (NH2)-SWFP-
(CONH2) retained efficient inhibitory potency but the peptide
(NH2)-WFP-(CONH2) was completely inactive towards Kly18
(Figure 5). The data clearly demonstrated that the serine in
position 1 was crucial for inhibition of Kly18 as all peptide versions
lacking this serine (15-8,15-10,15-11,15-12,15-13,15-14,15-15) lost
most or all of their Kly18 inhibition capacity (Figure 5). Therefore,
the Kly18 inhibiting peptide motif was expanded to (NH2)-SWFP-
(CONH2). A possible explanation is that in absence of serine the
presence of a charged amino group attached directly to the
Figure 4. The WFP peptide motif is reponsible for Kly18 binding and inhibition. Pre-incubation of Kly18 with peptide15, (NH2)-
SWFPLRSGGGS-(CONH2), and a control peptide (NH2)-SAAALRSGGGS-(CONH2), demonstrated that Kly18 inhibition could only be achieved with
peptide15. Therefore, we concluded that the WFP motif was not only important for Kly18 binding but also for Kly18 inhibition. Error bars represent
standard deviations between two experiments.
doi:10.1371/journal.pone.0048537.g004
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tryptophan of the (NH2)-WFP-(CONH2) motif could interfere with
the binding and inhibitory mechanism of the peptide. Interest-
ingly, full length peptide15 with an alanine substitution in position
3 (15-16), (NH2)-SWAPLRSGGGS-(CONH2), was also inactive
towards Kly18 (Figure 5). This demonstrated that the phenylana-
line was also crucial for the inhibitory activity of peptide15.
Detailed kinetic analysis of peptides 15-0.,15-5., 15-6. and 15-7.
revealed similar Ki values in the low micromolar area (Figure 6).
This demonstrated that peptide15 can be truncated to the tetra-
peptide (NH2)-SWFP-(CONH2) without compromising inhibitory
potency.
Peptide15 (SWFPL) Inhibits the Proteolytic Activity of
Intact Karylysin (Kly48) and Delays the Auto-processing
of Kly48 to Kly18
We next wanted to test if the inhibitory effect of peptide15 on
Kly18 could be reproduced on intact Karilysin (Kly48). The
experiment was performed essentially as described for Kly18 and
the results demonstrated a clear dose-response inhibition of Kly48
by (NH2)-SWFPL-(CONH2) (Figure 7A). Kly48 is unstable and
auto-processes itself into Kly38 and Kly18 over time. Conse-
quently, it was important to establish if SWFPL could modulate
the Kly48 auto-processing. As seen from the SDS-PAGE gels in
Figure 7B and 7C, (NH2)-SWFPL-(CONH2) inhibited the auto-
processesing efficiently and even after 48 hours there was still a
considerable amount of Kly48 present. Taken together these two
studies confirmed that peptide15 inhibited the proteolytic activity
of Kly48 and this dataset strongly suggested that it may be possible
to use peptide15 to lock Karilysin in the intact Kly48 form, and



















Shown are all possible truncation combinations of peptide15, while still
retaining the WFP motif. Each structure is given a number. The peptide15 lead
structure has the number 15-0. Structure 15-9 was too hydrophobic for
synthesis.
doi:10.1371/journal.pone.0048537.t001
Figure 5. Screening of truncated peptides demonstrates that a tetra-peptide version of peptide15 can inhibit Kly18. Different length
versions of peptide15 were tested for Kly18 inhibitory activity. All peptides were screened in a relatively high single concentration (87 mM) to reveal if
omission of single amino acid residues displayed dramatic effects on Kly18 inhibition. The data demonstrated that peptide15 can be limited to (NH2)-
SWFP-(CONH2) (structure 15-7) and still inhibit Kly18.
doi:10.1371/journal.pone.0048537.g005
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use that complex for crystallisation trials. This could reveal the
structure of the intact enzyme.
Expression of MBP-peptide15 Fusion Construct and
Specificity Test
In figure 8 a structural alignment of Kly18 and the catalytic
domain of human MMP-3 is shown and as is the case with most
human MMP’s (MMP-1, MMP-7-14), Kly18 and human MMP-3
are structurally similar [22]. It was therefore important to establish
if peptide15 was a general binder of MMP catalytic domains. To
develop a probe for cross-reactivity tests, peptide15 was expressed
as a MBP N-terminal fusion protein and purified in a simple one-
step purification strategy. Purity was judged to be greater than
90% by SDS-PAGE (data not shown) and the MBP-peptide15 was
used in ELISA to test cross-reactivity towards human MMP-3.
MBP-peptide15 bound Kly18 but not MMP-3, thereby underlin-
ing peptide15 specificity (figure 9A). By performing a control
ELISA experiment using MBP instead of MBP-peptide15, we
could confirm that the binding observed was due to the specific
interaction between peptide15 and Kly18 (Figure 9B).
As MMP catalytic domains are highly similar it is a challenge to
find specific peptides. This was demonstrated in a recent study,
which identified a cyclic MMP-9-binding peptide
(CTTHWGFTLC) by phage display with high affinity. However,
this peptide also had high affinity for MMP-2 [32]. Peptide phage
display has also been used to identify substrate specificity of
individual MMPs and by using a 15-mer peptide library Deng and
co-workers demonstrated that collagenase 3/MMP-13 has a
preference towards the peptide sequence GPLGMRGL. But three
other MMPs (stromelysin-1/MMP-3, gelatinase B/MMP-9 and
collagenase 1/MMP-1) had lower activity towards the isolated
peptide substrate [33]. Furthermore, a recent study demonstrated
that a unique MMP-11 substrate peptide could be isolated by
phage display, which explained why MMP-11 does not have any
activity towards substrates specific for other MMPs [34].
Consequently, one could argue that the peptide15 mode of action
is that of a substrate competitive inhibitor. This is especially
relevant due to the fact that the exact peptide sequence needed for
Kly18 substrate cleavage is yet to be fully elucidated [6]. To
explore this possibility peptide15 was incubated with or without a
large excess of Kly18 and the mixture was analyzed by liquid
chromatography mass spectrometry. The results demonstrated
that peptide15 could not be cleaved by Kly18 as the mass peak m/
z = 1149, corresponding to (NH2)-SWFPLRSGGGS-(CONH2),
was found in both preparations and no cleavage products were
found (data not shown).
Figure 6. The tetrapeptide displays a Ki value similar to that of the peptide 15 lead structure. Shown are chemdraw structure models of
the peptide versions 15-0, 15-5, 15-6 and 15-7. All truncated versions of peptide15 and intact peptide15 had low micromolar Ki values.
doi:10.1371/journal.pone.0048537.g006
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The development of MMP inhibitors is highly relevant, due to
the involvement of MMPs in several pathologies [23]. Some
candidate molecules act by blocking the MMP-active sites via
binding to the catalytic Zn2+ through chelators such as hydro-
xamate [23]. These approaches have been successful for MMP
inhibition. However, the inhibitors have a broad specificity
towards other MMPs due to very similar active site geometries
of matrix metalloproteinases [23]. An alternative approach to
specific MMP inhibitor design is to utilize larger molecules, such as
peptides, that interact with the active site as well as exosites unique
to individual MMPs [35]. Kly18 contains the metzincin MMP 3-
histidine zinc-binding motif (HEXXHXXGXXH) and Kly18 was
previously inhibited by small molecules chelators (EDTA, 1,10-
phenanthroline) similar to mammalian MMPs [6]. Furthermore,
the active site of the Kly18 structure had the classical MMP
composition with small deviations in the specificity loop (seen as a
red circle in Figure 8) [22]. As peptide15 binds exclusively to
Kly18 and at the same time inhibits the enzyme, peptide15 may
act by a combined effect of active site targeting and specificity loop
exosite interaction. However, detailed structural analysis of Kly18-
peptide15 co-crystals will provide final proof on the inhibition
mechanism.
Conclusions
Periodontitis is a devastating disease of great discomfort to
affected patients. Furthermore, recent findings link periodontitis to
inflammatory diseases like rheumatoid arthritis, thereby further
underlining the importance of disease treatment and containment
[36]. Inhibitors of the periodontopathogen-derived proteases by
small molecules, peptides or antibodies represent a rational
approach to disease management. Inhibitors toward the most
relevant proteases, of which Karilysin could be one, might be
Figure 7. SWFPL inhibits the proteolytic activity of intact Karilysin (Kly48) and delays the auto-processing of Kly48 to Kly18. A) Kly48
was pre-incubated with SWFPL in varying concentrations (2.3 mM to 55.6 mM) followed by addition of the substrate FITC-casein. The SWFPL inhibitory
effect was seen as a decrease in Relative Fluorescence Units (RFU) in a dose-response manner. Error bars represent standard deviations between three
experiments. B+C) Intact Karilysin (Kly48) at 13 mM was incubated alone (B) or with the peptide inhibitor (C) at 455 mM. At indicated time points
samples were withdrawn for SDS-PAGE analysis. It is clear that SWFPL inhibited the time-dependent autoprocessing of Kly48 to Kly38 and Kly18. Even
after 48 hours a significant amount of Kly48 was still present.
doi:10.1371/journal.pone.0048537.g007
Figure 8. Structural alignment of the catalytic domains from
Karilysin (Kly18) and human Matrix Metalloprotease-3 (MMP-
3). MMP-3 is seen in green and Kly18 is seen in grey. The figure was
prepared using Pymol (DeLano Scientific LLC) and the coordinate files
1CQR (MMP-3) and 2XS3 (Kly18). The structure alignment was
performed using the ‘align’ function in PyMol. The Kly18 was
structurally similar to MMP-3 as well as other mammalian MMP’s
(MMP-1 to 3, MMP-7 to MMP-14, MMP-16 and MMP-20) (Cerda-Costa
et al. 2011). The figure displays the zinc (yellow sphere) that is
coordinated by the three active site histidines (H155, H159 and H165).
The specificity loop is indicated with a red circle.
doi:10.1371/journal.pone.0048537.g008
Tetrapeptide Inhibitor of Karilysin
PLOS ONE | www.plosone.org 9 October 2012 | Volume 7 | Issue 10 | e48537
applied as a combination therapy in the fight against the
periodontopathogens of the ‘red complex’. These inhibitors could
be formulated in existing media, such as mouth wash, tooth paste
or even chewing gum.
In this study, the first inhibitor of Karilysin was identified and
characterized. The results supplied us with a detailed understand-
ing of which amino acid residues were important for the inhibitory
function of peptide15. The peptide will be a valuable probe in
structure-function studies of Karilysin and detailed co-crystallisa-
tion studies can reveal the underlying molecular mechanism for
the inhibition. From co-crystallisation structural data it may be
possible to design peptidomimetics with improved Ki-values.
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